Evidence map›Paper›PMID 35368961›Full record

Trial reportJournal of healthcare engineering2022

Efficacy of Jiedu Pingsou Decoction Combined with Azithromycin in the Treatment of Children with Mycoplasma Pneumonia and Its Effects on Inflammatory Factors and Immune Function.

Shaoli Lin, Shiyun Wang, Juan Zhang, Min Zhuang, Zhen Meng, Jianhua Liu

RetractedOpen access · hybridAbstract readRandomized Controlled TrialRetracted Publication
In one paragraph

Trial report in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Shaoli LinDepartment of Pediatrics, Yantaishan Hospital, Yantai 264000, Shandong, China.ORCID 0000-0002-3654-4902
Shiyun WangDepartment of Pediatrics (I), Jiyang People's Hospital, Jinan 251400, Shandong, China.ORCID 0000-0003-1729-2284
Juan ZhangDepartment of Traditional Chinese Medicine, Qingdao Eighth People's Hospital, Qingdao 266000, Shandong, China.ORCID 0000-0003-3935-3594
Min ZhuangDepartment of Endocrinology, Zhangqiu District People's Hospital, Jinan 250200, Shandong, China.ORCID 0000-0003-4495-2954
Zhen MengDepartment of Ultrasound, Zhangqiu District People's Hospital, Jinan 250200, Shandong, China.ORCID 0000-0003-2031-2151
Jianhua LiuInfirmary of Veteran Cadre Rest Center, Zhangqiu District People's Hospital, Jinan 250200, Shandong, China.ORCID 0000-0002-5808-3027
Zhangqiu City People's Hospital · CNJinan City People's Hospital · CNQingdao Eighth People's Hospital · CNYantaishan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The purpose of this study is to detect the clinical efficacy of Jiedu Pingsou Decoction combined with azithromycin in the treatment of children with mycoplasma pneumonia and the effect on inflammatory factors and immune function in children. Methods: A total of 68 children with mycoplasma pneumonia in our hospital from January 2021 to January 2022 were included in this study, and they were randomly divided into the control group and the observation group with 34 cases in each group. The children in the control group were treated with azithromycin, and the children in the observation group were treated with Jiedu Pingsou Decoction on this basis. The clinical manifestations, treatment effects, blood routine, serum inflammatory factor levels, and T cell subsets before and after treatment were compared between the two groups. Results: The total effective rate in the observation group was 94.12%, which was higher than that in the control group, which was 82.35%, and the difference between the two groups was statistically significant ( Conclusion: Jiedu Pingsou Decoction combined with azithromycin can effectively improve the levels of T cell subsets, immune function, and inflammatory factors in children with mycoplasma pneumonia, improve clinical symptoms, and is safe and stable, and can be used in clinical practice.

Indexed as

AzithromycinPneumonia, MycoplasmaChildHumansImmunityAzithromycin

Identifiers

PMID35368961
PMCPMC8970864
OpenAlexW4220711019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.